Tanzania - English - Tanzania Medicinces & Medical Devices Authority

lab equip limited, tanzania - pharmaceutical refrigerator -

Nigeria - English - NAFDAC (National Agency for Food and Drugs Administration and Control)

dafra pharma gmbh - artemether 180mg, lumefantrine 1080mg - co-artesiane is indicated for the treatment of malaria in children, caused by all forms of plasmodium including severe malaria caused by multiple drug resistant strains of p. falciparum. in case of a p. vivax malaria infection an additional treatment with primaquine may be required.

Philippines - English - FDA (Food And Drug Administration)

sun pharma philippines, inc.; distributor: adp pharma corporation - co-amoxiclav - film-coated tablet - 625mg

Philippines - English - FDA (Food And Drug Administration)

unosource pharma ltd.; importer: ambica international corp.; distributor: aisec farma corporation - co-amoxiclav - film-coated tablet - 875mg /125 mg

Philippines - English - FDA (Food And Drug Administration)

prime pharmaceuticals pvt. ltd.; importer: aglobal care inc.; distributor: aglobal care inc. - co-amoxiclav - powder for suspension - 457mg/5ml

Philippines - English - FDA (Food And Drug Administration)

sapphire lifesciences pvt. ltd.; importer: ollen pharma trading, inc.; distributor: ollen pharma trading, inc. - co-amoxiclav - film-coated tablet - 375mg

Australia - English - Department of Health (Therapeutic Goods Administration)

novartis pharmaceuticals australia pty ltd - valsartan, quantity: 320 mg; hydrochlorothiazide, quantity: 25 mg - tablet, film coated - excipient ingredients: microcrystalline cellulose; colloidal anhydrous silica; magnesium stearate; crospovidone; hypromellose; purified talc; iron oxide yellow; macrogol 4000; titanium dioxide - co-diovan is indicated for the treatment of hypertension. treatment should not be initiated with these combinations.

Australia - English - Department of Health (Therapeutic Goods Administration)

novartis pharmaceuticals australia pty ltd - hydrochlorothiazide, quantity: 12.5 mg; valsartan, quantity: 320 mg - tablet, film coated - excipient ingredients: colloidal anhydrous silica; crospovidone; microcrystalline cellulose; magnesium stearate; hypromellose; purified talc; iron oxide red; macrogol 4000; iron oxide black; titanium dioxide - co-diovan is indicated for the treatment of hypertension. treatment should not be initiated with these combinations.

Australia - English - Department of Health (Therapeutic Goods Administration)

novartis pharmaceuticals australia pty ltd - valsartan, quantity: 160 mg; hydrochlorothiazide, quantity: 25 mg - tablet, film coated - excipient ingredients: microcrystalline cellulose; crospovidone; magnesium stearate; colloidal anhydrous silica; hypromellose; purified talc; iron oxide yellow; macrogol 4000; iron oxide red; iron oxide black; titanium dioxide - co-diovan is indicated for the treatment of hypertension. treatment should not be initiated with these combinations.

Australia - English - Department of Health (Therapeutic Goods Administration)

novartis pharmaceuticals australia pty ltd - hydrochlorothiazide, quantity: 12.5 mg; valsartan, quantity: 160 mg - tablet, film coated - excipient ingredients: crospovidone; microcrystalline cellulose; titanium dioxide; purified talc; iron oxide red; macrogol 8000; magnesium stearate; hypromellose; colloidal anhydrous silica - co-diovan is indicated for the treatment of hypertension. treatment should not be initiated with these combinations.